All IndicationsRespiratoryApprovedPhase 3Phase 3Phase 2Phase 2
🫁
Myelofibrosis
3
Companies
7
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
IPN
Ipsen
navtemadlin
KPTI
Karyopharm
Selinexor
GERN
Geron Corporation
Imetelstat
GERN
Geron Corporation
Imetelstat 4.7 mg/kg
KPTI
Karyopharm Therapeutics Inc.
Selinexor 60 mg
KPTI
Karyopharm
Selinexor Plus Ruxolitinib
KPTI
Karyopharm
Selinexor plus Ruxolitinib
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| IPN Ipsen | navtemadlin | Approved | — | — | — |
| KPTI Karyopharm | Selinexor | Phase 3 | — | — | — |
| GERN Geron Corporation | Imetelstat | Phase 3 | — | — | — |
| GERN Geron Corporation | Imetelstat 4.7 mg/kg | Phase 2 | — | — | — |
| KPTI Karyopharm Therapeutics Inc. | Selinexor 60 mg | Phase 2 | — | — | — |
| KPTI Karyopharm | Selinexor Plus Ruxolitinib | — | — | — | — |
| KPTI Karyopharm | Selinexor plus Ruxolitinib | — | — | — | — |
Development Stage Distribution
Unknown
2
Approved
1
Phase 3
2
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.